Survival Prolongation by Rationale Innovative Genomics
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- RAZELLE KURZROCK, MD
Medical College of Wisconsin, Milwaukee, WI, USA
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chaim Sheba Medical Center
Ramat Gan, Israel
- Centre Hospitalier Luxembourg
Luxembourg, Luxembourg
- Vall Hebron Institute of Oncology
Barcelona, Spain
- Ucsd Moores Cancer Center
La Jolla, California, United States
- Avera Cancer Center
Sioux Falls, South Dakota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Nov 2017
- Primary completion
- 29 Dec 2022
- Completion
- 29 Dec 2022
- Last update posted
- 18 Dec 2023
- Registered enrollment
- 15
- Registry id
- NCT03386929
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.